Haemonetics reported second-quarter revenue of $339.4 million, beating analyst estimates of $330.2 million, with adjusted earnings per share of $1.14 versus expectations of $1.08. During the earnings call, analysts questioned management on topics including share gains in Interventional Technologies, gross margin progression, and the adoption curve for the Persona PLUS plasma device. CEO Christopher Simon said the Persona PLUS rollout is ahead of schedule and that there is no evidence of capital budget tightening affecting TEG placements. CFO James D'Arecca attributed expected margin expansion to stable SG&A and favorable product mix from Persona PLUS.
Haemonetics CorporationQ2 earnings and EPS beat estimates, with management citing margin expansion from product mix.